Opioids and cannabinoids interactions: Involvement in pain management

Current Drug Targets

Volumn 11, Issue 4, 2010, Pages 462-473

  Desroches, Julie ^a   Beaulieu, Pierre ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Antinociception; Bidirectional interactions; Cannabinoids; Clinical implications; Opioids; Synergism

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE METHANESULFONATE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANANDAMIDE; ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTISERUM; BETA FUNALTREXAMINE; CANNABINOID; CANNABINOID RECEPTOR; CODEINE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DELTORPHIN; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; ENDOMORPHIN 1; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; MORPHINE; N,N DIALLYLTYROSYL 2 METHYLALANYL 2 METHYLALANYLPHENYLALANYLLEUCINE; NALOXONE; NALTRINDOLE; NOLADIN ETHER; NORBINALTORPHIMINE; OPIATE; OPIATE AGONIST; OPIATE ANTAGONIST; OPIATE RECEPTOR; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; URB 602;

ANALGESIA; ANTINOCICEPTION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; KNOCKOUT MOUSE; NOCICEPTION; NONHUMAN; PAIN; REVIEW;

ANALGESIA; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; ANIMALS; BRAIN; CANNABINOIDS; DRUG INTERACTIONS; ENDOCANNABINOIDS; HUMANS; OPIOID PEPTIDES; PAIN; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 77950803144     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010790980303     Document Type: Review

References (204)

1. Manzanares J, Corchero J, Romero J, Fernández-Ruiz JJ, Ramos JA, Fuentes JA. Pharmacological and biochemical interactions between opioids and cannabinoids. Trends Pharmacol Sci 1999; 20: 287-294 (Pubitemid 29301682)
2. Massi P, Vaccani A, Romorini S, Parolaro D. Comparative characterization in the rat of the interaction between cannabinoids and opiates for their immunosuppressive and analgesic effects. J Neuroimmunol 2001; 117: 116-124 (Pubitemid 32595499)
3. Maldonado R, Valverde O. Participation of the opioid system in cannabinoid-induced antinociception and emotional-like responses. Eur Neuropsychopharmacol 2003; 13: 401-410 (Pubitemid 37433961)
4. Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 2004; 74: 1317-1324.
5. Bidaut-Russell M, Devane WA, Howlett AC. Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain. J Neurochem 1990; 55: 21-26 (Pubitemid 20187799)
6. Childers SR, Fleming L, Konkoy C, Marckel D, Pacheco M, Sexton T, et al. Opioid and cannabinoid receptor inhibition of adenylyl cyclase in brain. Ann NY Acad Sci 1992;654: 33-51.
7. Howlett AC. Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 1995; 35: 607-634
8. Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L, et al. Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 2001; 21: 5344-5350 (Pubitemid 32622960)
9. Yasuda K, Raynor K, Kong H, Breder CD, Takeda J, Reisine T, et al. Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. Proc Natl Acad Sci USA 1993; 90: 6736-6740 (Pubitemid 23207288)
10. Evans CJ, Keith DE Jr, Morrison H, Magendzo K, Edwards RH. Cloning of a delta opioid receptor by functional expression. Science 1992; 258: 1952-1955
11. Kieffer BL, Befort K, Gaveriaux-Ruff C, Hirth CG. The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci USA 1992; 89: 12048-12052 (Pubitemid 23004782)
12. Chen Y, Mestek A, Liu J, Yu L. Molecular cloning of a rat kappa opioid receptor reveals sequence similarities to the mu and delta opioid receptors. Biochem J 1993; 295: 625-628 (Pubitemid 23323479)
13. Mollereau C, Parmentier M, Mailleux P, Butour JL, Moisand C, Chalon P, et al. ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett 1994; 341: 33-38
14. Akil H, Owens C, Gutstein H, Taylor L, Curran E, Watson S. Endogenous opioids: overview and current issues. Drug Alcohol Depend 1998; 51: 127-140 (Pubitemid 28353761)
15. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ. Anatomy of CNS opioid receptors. Trends Neurosci 1988; 11: 308-314
16. Mansour A, Fox CA, Akil H, Watson SJ. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci 1995; 18: 22-29
17. Arvidsson U, Riedl M, Chakrabarti S, Lee JH, Nakano AH, Dado RJ, et al. Distribution and targeting of a mu-opioid receptor (MOR1) in brain and spinal cord. J Neurosci 1995; 15: 3328-3341
18. Maekawa K, Minami M, Yabuuchi K, Toya T, Katao Y, Hosoi Y, et al. In situ hybridization study of mu- and kappa-opioid receptor mRNAs in the rat spinal cord and dorsal root ganglia. Neurosci Lett 1994; 168: 97-100.
19. Robertson B, Schulte G, Elde R, Grant G. Effects of sciatic nerve injuries on delta -opioid receptor and substance P immunoreactivities in the superficial dorsal horn of the rat. Eur J Pain 1999; 3: 115-129. (Pubitemid 29290765)
20. Chen SR, Sweigart KL, Lakoski JM, Pan HL. Functional mu opioid receptors are reduced in the spinal cord dorsal horn of diabetic rats. Anesthesiology 2002; 97: 1602-1608
21. Pettersson LM, Sundler F, Danielsen N. Expression of orphanin FQ/nociceptin and its receptor in rat peripheral ganglia and spinal cord. Brain Res 2002; 945: 266-275 (Pubitemid 34786629)
22. Dado RJ, Law PY, Loh HH, Elde R. Immunofluorescent identification of a delta (delta)-opioid receptor on primary afferent nerve terminals. Neuroreport 1993; 5: 341-344 (Pubitemid 24026270)
23. Wang H, Wessendorf MW. Equal proportions of small and large DRG neurons express opioid receptor mRNAs. J Comp Neurol 2001; 429: 590-600. (Pubitemid 32011855)
24. Stein C, Millan MJ, Shippenberg TS, Peter K, Herz A. Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors. J Pharmacol Exp Ther 1989; 248: 1269-1275 (Pubitemid 19100783)
25. Cheng PY, Liu-Chen LY, Pickel VM. Dual ultrastructural immunocytochemical labeling of mu and delta opioid receptors in the superficial layers of the rat cervical spinal cord. Brain Res 1997; 778: 367-380
26. Berg KA, Patwardhan AM, Sanchez TA, Silva YM, Hargreaves KM, Clarke WP. Rapid modulation of micro-opioid receptor signaling in primary sensory neurons. J Pharmacol Exp Ther 2007; 321: 839-847 (Pubitemid 46762685)
27. Calvo CF, Cesselin F, Gelman M, Glowinski J. Identification of an opioid peptide secreted by rat embryonic mixed brain cells as a promoter of macrophage migration. Eur J Neurosci 2000; 12: 2676-2684
28. Turchan-Cholewo J, Dimayuga FO, Ding Q, Keller JN, Hauser KF, Knapp PE, et al. Cell-specific actions of HIV-Tat and morphine on opioid receptor expression in glia. J Neurosci Res 2008; 86: 2100-2110
29. Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan BA, Morris HR. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature 1975; 258: 577-580
30. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Phys 2008; 11: S133-53.
31. Eguchi M. Recent advances in selective opioid receptor agonists and antagonists. Med Res Rev 2004; 24: 182-212. (Pubitemid 38230679)
32. Gutstein HB, Akil H. In: Goodman & Gilman's, The pharmacological basis of therapeutics. McGraw Hill, New York 2006; 547-590.
33. Moises HC, Rusin KI, Macdonald RL. Mu- and kappa-opioid receptors selectively reduce the same transient components of high-threshold calcium current in rat dorsal root ganglion sensory neurons. J Neurosci 1994; 14: 5903-5916 (Pubitemid 2159727)
34. Acosta CG, López HS. delta opioid receptor modulation of several voltage-dependent Ca(2+) currents in rat sensory neurons. J Neurosci 1999; 19: 8337-8348
35. Beedle AM, McRory JE, Poirot O, Doering CJ, Altier C, Barrere C, et al. Agonist-independent modulation of N-type calcium channels by ORL1 receptors. Nat Neurosci 2004; 7: 118-125 (Pubitemid 38129787)
36. 2+ currents. Neuroscience 2004; 153: 1256-1267
37. Schneider SP, Eckert WA, Light AR. Opioid-activated post-synaptic, inward rectifying potassium currents in whole cell recordings in substantia gelatinosa neurons. J Neurophysiol 1998; 80: 2954-2962
38. Marker CL, Luján R, Colón J, Wickman K. Distinct populations of spinal cord lamina II interneurons expressing G-protein-gated potassium channels. J Neurosci 2006; 26: 12251-12259 (Pubitemid 44808392)
39. Fields HL, Heinricher MM, Mason P. Neurotransmitters in nociceptive modulatory circuits. Annu Rev Neurosci 1991; 14: 219-245
40. Mason P. Central mechanisms of pain modulation. Curr Opin Neurobiol 1999; 9: 436-441
41. Fields H. State-dependent opioid control of pain. Nat Rev Neurosci 2004; 5: 565-575
42. Parsons CG, Członkowski A, Stein C, Herz A. Peripheral opioid receptors mediating antinociception in inflammation. Activation by endogenous opioids and role of the pituitary-adrenal axis. Pain 1990; 41: 81-93.
43. Stein C, Hassan AH, Przewłocki R, Gramsch C, Peter K, Herz A. Opioids from immunocytes interact with receptors on sensory nerves to inhibit nociception in inflammation. Proc Natl Acad Sci U S A 1990; 87: 5935-5939 (Pubitemid 20240404)
44. Maldonado R, Valverde O, Turcaud S, Fournié-Zaluski MC, Roques BP. Antinociceptive response induced by mixed inhibitors of enkephalin catabolism in peripheral inflammation. Pain 1994; 58: 77-83. (Pubitemid 24221820)
45. Hylden JL, Thomas DA, Iadarola MJ, Nahin RL, Dubner R. Spinal opioid analgesic effects are enhanced in a model of unilateral inflammation/ hyperalgesia: possible involvement of noradrenergic mechanisms. Eur J Pharmacol 1991; 194: 135-143
46. Taylor F, Dickenson A. Nociceptin/orphanin FQ. A new opioid, a new analgesic? Neuroreport 1998; 9: R65-70.
47. Przewłocka B, Mika J, Labuz D, Toth G, Przewłocki R. Spinal analgesic action of endomorphins in acute, inflammatory and neuropathic pain in rats. Eur J Pharmacol 1999; 367: 189-196 (Pubitemid 29106370)
48. Jessop DS. Endomorphins as agents for the treatment of chronic inflammatory disease. BioDrugs 2006; 20: 161-166 (Pubitemid 43793517)
49. Mao J, Price DD, Mayer DJ. Experimental mononeuropathy reduces the antinociceptive effects of morphine: implications for common intracellular mechanisms involved in morphine tolerance and neuropathic pain. Pain 1995; 61: 353-364
50. Wegert S, Ossipov MH, Nichols ML, Bian D, Vanderah TW, Malan TP Jr, et al. Differential activities of intrathecal MK-801 or morphine to alter responses to thermal and mechanical stimuli in normal or nerve-injured rats. Pain 1997; 71: 57-64. (Pubitemid 27245231)
51. Inglis JJ, McNamee KE, Chia SL, Essex D, Feldmann M, Williams RO, et al. Regulation of pain sensitivity in experimental osteoarthritis by the endogenous peripheral opioid system. Arthritis Rheum 2008; 58: 3110-3119
52. Ossipov MH, Lopez Y, Nichols ML, Bian D, Porreca F. The loss of antinociceptive efficacy of spinal morphine in rats with nerve ligation injury is prevented by reducing spinal afferent drive. Neurosci Lett 1995; 199: 87-90.
53. Narita M, Kuzumaki N, Suzuki M, Narita M, Oe K, Yamazaki M, et al. Increased phosphorylated-mu-opioid receptor immunoreactivity in the mouse spinal cord following sciatic nerve ligation. Neurosci Lett 2004; 354: 148-152 (Pubitemid 38032855)
54. Hutchinson MR, Bland ST, Johnson KW, Rice KC, Maier SF, Watkins LR. Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. Scientific World Journal 2007; 7: 98-111.
55. Hutchinson MR, Northcutt AL, Chao LW, Kearney JJ, Zhang Y, Berkelhammer DL, et al. Minocycline suppresses morphine-induced respiratory depression, suppresses morphine-induced reward, and enhances systemic morphine-induced analgesia. Brain Behav Immun 2008; [Epub ahead of print] PMID: 18706994
56. Mika J. Modulation of microglia can attenuate neuropathic pain symptoms and enhance morphine effectiveness. Pharmacol Rep 2008; 60: 297-307.
57. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-564 (Pubitemid 20238806)
58. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-65 (Pubitemid 23305569)
59. Manning BH, Martin WJ, Meng ID. The rodent amygdala contributes to the production of cannabinoid-induced antinociception. Neuroscience 2003; 120: 1157-1170
60. Martin WJ, Hohmann AG, Walker JM. Suppression of noxious stimulus-evoked activity in the ventral posterolateral nucleus of the thalamus by a cannabinoid agonist: correlation between electrophysiological and antinociceptive effects. J Neurosci 1996; 16: 6601-6611
61. Cristino L, de Petrocellis L, Pryce G, Baker D, Guglielmotti V, Di Marzo V. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 2006; 139: 1405-1415
62. Mailleux P, Vanderhaeghen JJ. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 1992; 48: 655-668
63. Tsou K, Brown S, Sañudo-Peña MC, Mackie K, Walker JM. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 1998; 83: 393-411. (Pubitemid 28062631)
64. Lichtman AH, Cook SA, Martin BR. Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement. J Pharmacol Exp Ther 1996; 276: 585-593 (Pubitemid 126660496)
65. Luo C, Kumamoto E, Furue H, Chen J, Yoshimura M. Anandamide inhibits excitatory transmission to rat substantia gelatinosa neurones in a manner different from that of capsaicin. Neurosci Lett 2002; 321: 17-20. (Pubitemid 34185488)
66. Morisset V, Urban L. Cannabinoid-induced presynaptic inhibition of glutamatergic EPSCs in substantia gelatinosa neurons of the rat spinal cord. J Neurophysiol 2001; 86: 40-48 (Pubitemid 32623210)
67. Hohmann AG. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. Chem Phys Lipids 2002; 121: 173-190
68. Walczak JS, Pichette V, Leblond F, Desbiens K, Beaulieu P. Behavioral, pharmacological and molecular characterization of the saphenous nerve partial ligation: a new model of neuropathic pain. Neuroscience 2005; 132: 1093-1102 (Pubitemid 40602543)
69. Walczak JS, Pichette V, Leblond F, Desbiens K, Beaulieu P. Characterization of chronic constriction of the saphenous nerve, a model of neuropathic pain in mice showing rapid molecular and electrophysiological changes. J Neurosci Res 2006; 83: 1310-1322 (Pubitemid 43668014)
70. Agarwal N, Pacher P, Tegeder I, Amaya F, Constantin CE, Brenner GJ, et al. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat Neurosci 2007; 10: 870-879
71. Lever IJ, Rice AS. Cannabinoids and pain. Handb Exp Pharmacol 2007; 177: 265-306.
72. Hohmann AG, Herkenham M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience 1999; 90: 923-931 (Pubitemid 29156757)
73. Bridges D, Rice AS, Egertová M, Elphick MR, Winter J, Michael GJ. Localisation of cannabinoid receptor 1 in rat dorsal root ganglion using in situ hybridisation and immunohistochemistry. Neuroscience 2003; 119: 803-812 (Pubitemid 36694807)
74. Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995; 232: 54-61.
75. Schatz AR, Lee M, Condie RB, Pulaski JT, Kaminski NE. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol 1997; 142: 278-287 (Pubitemid 28381018)
76. Jhaveri MD, Sagar DR, Elmes SJ, Kendall DA, Chapman V. Cannabinoid CB2 receptor-mediated anti-nociception in models of acute and chronic pain. Mol Neurobiol 2007; 36: 26-35. (Pubitemid 351360358)
77. Di Marzo V. Endocannabinoids: synthesis and degradation. Rev Physiol Biochem Pharmacol 2008; 160: 1-24.
78. Jhaveri MD, Richardson D, Chapman V. Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br J Pharmacol 2007; 152: 624-632 (Pubitemid 350034979)
79. Hohmann AG, Suplita RL. Endocannabinoid mechanisms of pain modulation. AAPS J 2006; 8: E693-708.
80. Cravatt BF, Lichtman AH. The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol 2004; 61: 149-160
81. Di Marzo V, De Petrocellis L, Bisogno T. The biosynthesis, fate and pharmacological properties of endocannabinoids. Handb Exp Pharmacol 2005; 168: 147-185
82. Venance L, Maldonado R, Manzoni O. [Endocannabinoids in the central nervous system]. Med Sci (Paris) 2004; 20: 45-53.
83. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003; 4: 873-884
84. Baker D, Pryce G, Giovannoni G, Thompson AJ. The therapeutic potential of cannabis. Lancet Neurol 2003; 2: 291-298
85. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258:1946-1949 (Pubitemid 23026736)
86. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50: 83-90.
87. Pertwee RG. The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes (Lond) 2006; 30: S13-8.
88. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 2008; 7: 438-455
89. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996; 384: 83-87
90. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, et al. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A 2002; 99: 10819-10824
91. Di Marzo V, Bisogno T, Sugiura T, Melck D, De Petrocellis L. The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochem J 1998; 331:15-19 (Pubitemid 28163951)
92. Goparaju SK, Ueda N, Yamaguchi H, Yamamoto S. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett 1998; 422: 69-73. (Pubitemid 28052868)
93. Bisogno T, Ligresti A, Di Marzo V. The endocannabinoid signalling system: biochemical aspects. Pharmacol Biochem Behav 2005; 81: 224-238 (Pubitemid 40812404)
94. Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003; 9: 76-81. (Pubitemid 36098263)
95. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA 2001; 98: 9371-9376 (Pubitemid 32743923)
96. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, et al. An endocannabinoid mechanism for stress-induced analgesia. Nature 2005; 435: 1108-1112
97. De Petrocellis L, Cascio MG, Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol 2004; 141: 765-774 (Pubitemid 38446177)
98. Degroot A, Nomikos GG. In vivo neurochemical effects induced by changes in endocannabinoid neurotransmission. Curr Opin Pharmacol 2007; 7: 62-68
99. Maione S, Bisogno T, de Novellis V, Palazzo E, Cristino L, Valenti M, et al. Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J Pharmacol Exp Ther 2006; 316: 969-982
100. Jaggar SI, Hasnie FS, Sellaturay S, Rice AS. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 1998; 76: 189-199 (Pubitemid 28304956)
101. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature 1998; 394: 277-281 (Pubitemid 28335039)
102. Guindon J, Desroches J, Beaulieu P. The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors. Br J Pharmacol 2007; 150: 693-701. (Pubitemid 46440208)
103. Mitrirattanakul S, Ramakul N, Guerrero AV, Matsuka Y, Ono T, Iwase H, et al. Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. Pain 2006; 126: 102-114 (Pubitemid 44781351)
104. Palazzo E, de Novellis V, Petrosino S, Marabese I, Vita D, Giordano C, et al. Neuropathic pain and the endocannabinoid system in the dorsal raphe: pharmacological treatment and interactions with the serotonergic system. Eur J Neurosci 2006; 24: 2011-2020 (Pubitemid 44583485)
105. La Rana G, Russo R, Campolongo P, Bortolato M, Mangieri RA, Cuomo V, et al. Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4- hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]. J Pharmacol Exp Ther 2006; 317: 1365-1371 (Pubitemid 43764143)
106. Petrosino S, Palazzo E, de Novellis V, Bisogno T, Rossi F, Maione S, et al. Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology 2007; 52: 415-422 (Pubitemid 46127787)
107. Desroches J, Guindon J, Lambert C, Beaulieu P. Modulation of the anti-nociceptive effects of 2-arachidonoyl glycerol by peripherally administered FAAH and MGL inhibitors in a neuropathic pain model. Br J Pharmacol 2008; 155: 913-924
108. Khasabova IA, Khasabov SG, Harding-Rose C, Coicou LG, Seybold BA, Lindberg AE, et al. A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain. J Neurosci 2008; 28: 11141-11152
109. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999; 283: 401-404 (Pubitemid 129501104)
110. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA 1999; 96: 5780-5785 (Pubitemid 29234695)
111. Ibrahim MM, Rude ML, Stagg NJ, Mata HP, Lai J, Vanderah TW, et al. CB2 cannabinoid receptor mediation of antinociception. Pain 2006; 122: 36-42.
112. Bloom AS, Dewey WL. A comparison of some pharmacological actions of morphine and delta9-tetrahydrocannabinol in the mouse. Psychopharmacology (Berl) 1978; 57: 243-248
113. Cichewicz DL, Martin ZL, Smith FL, Welch SP. Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification. J Pharmacol Exp Ther 1999; 289: 859-867
114. Dogrul A, Gul H, Akar A, Yildiz O, Bilgin F, Guzeldemir E. Topical cannabinoid antinociception: synergy with spinal sites. Pain 2003; 105: 11-16 (Pubitemid 37167991)
115. Hohmann AG, Tsou K, Walker JM. Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. J Neurophysiol 1999; 81: 575-583 (Pubitemid 29264504)
116. Hohmann AG, Tsou K, Walker JM. Intrathecal cannabinoid administration suppresses noxious stimulus-evoked Fos protein-like immunoreactivity in rat spinal cord: comparison with morphine. Zhongguo Yao Li Xue Bao 1999; 20: 1132-1136
117. Manzanares J, Corchero J, Romero J, Fernandez-Ruiz JJ, Ramos JA, Fuentes JA. Chronic administration of cannabinoids regulates proenkephalin mRNA levels in selected regions of the rat brain. Brain Res Mol Brain Res 1998; 55: 126-132 (Pubitemid 28236597)
118. Welch SP, Stevens DL. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J Pharmacol Exp Ther 1992; 262: 10-18.
119. Ghosh P, Bhattacharya SK. Cannabis-induced potentiation of morphine analgesia in rat - role of brain monoamines. Indian J Med Res 1979; 70: 275-280 (Pubitemid 10216962)
120. Mechoulam R, Lander N, Srebnik M, Zamir I, Breuer A, Shalita B, et al. In: The Cannabinoids: chemical, pharmacological and therapeutic aspects. Academic Press, New York 1984; 777-793
121. Massi P, Vaccani A, Romorini S, Parolaro D. Comparative characterization in the rat of the interaction between cannabinoids and opiates for their immunosuppressive and analgesic effects. J Neuroimmunol 2001; 117: 116-124 (Pubitemid 32595499)
122. Meng ID, Manning BH, Martin WJ, Fields HL. An analgesia circuit activated by cannabinoids. Nature 1998; 395: 381-383
123. Wilson RS, May EL. Analgesic properties of the tetrahydrocannabinols, their metabolites, and analogs. J Med Chem 1975; 18: 700-703
124. Welch SP. Blockade of cannabinoid-induced antinociception by naloxone benzoylhydrazone (NalBZH). Pharmacol Biochem Behav 1994; 49: 929-934
125. Reche I, Fuentes JA, Ruiz-Gayo M. Potentiation of delta 9- tetrahydrocannabinol-induced analgesia by morphine in mice: involvement of mu- and kappa-opioid receptors. Eur J Pharmacol 1996; 318: 11-16 (Pubitemid 27033197)
126. Smith FL, Cichewicz D, Martin ZL, Welch SP. The enhancement of morphine antinociception in mice by delta9- tetrahydrocannabinol. Pharmacol Biochem Behav 1998; 60: 559-566 (Pubitemid 28282699)
127. Martin BR. Structural requirements for cannabinoid-induced antinociceptive activity in mice. Life Sci 1985; 36: 1523-1530 (Pubitemid 15108036)
128. Welch SP. Blockade of cannabinoid-induced antinociception by norbinaltorphimine, but not N,N-diallyl-tyrosine-Aib-phenylalanine-leucine, ICI 174,864 or naloxone in mice. J Pharmacol Exp Ther 1993; 265: 633-640
129. Haller VL, Cichewicz DL, Welch SP. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice. Eur J Pharmacol 2006; 546: 60-68
130. Smith FL, Fujimori K, Lowe J, Welch SP. Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. Pharmacol Biochem Behav 1998; 60: 183-191 (Pubitemid 28236629)
131. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther 1994; 270: 219-227 (Pubitemid 24229631)
132. Reche I, Fuentes JA, Ruiz-Gayo M. A role for central cannabinoid and opioid systems in peripheral delta 9-tetrahydrocannabinol-induced analgesia in mice. Eur J Pharmacol 1996; 301: 75-81. (Pubitemid 26169744)
133. Welch SP, Dunlow LD, Patrick GS, Razdan RK. Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception. J Pharmacol Exp Ther 1995; 273:1235-1244
134. Smith PB, Welch SP, Martin BR. Interactions between delta 9- tetrahydrocannabinol and kappa opioids in mice. J Pharmacol Exp Ther 1994; 268: 1381-1387 (Pubitemid 24100357)
135. Pugh G Jr, Smith PB, Dombrowski DS, Welch SP. The role of endogenous opioids in enhancing the antinociception produced by the combination of delta 9-tetrahydrocannabinol and morphine in the spinal cord. J Pharmacol Exp Ther 1996; 279 : 608-616
136. Pugh G Jr, Mason DJ Jr, Combs V, Welch SP. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord. J Pharmacol Exp Ther 1997; 281: 730-737 (Pubitemid 27203805)
137. Mason DJ Jr, Lowe J, Welch SP. Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception. Eur J Pharmacol 1999; 378: 237-248 (Pubitemid 29392924)
138. Pugh G Jr, Abood ME, Welch SP. Antisense oligodeoxynucleotides to the kappa-1 receptor block the antinociceptive effects of delta 9-THC in the spinal cord. Brain Res 1995; 689: 157-158
139. Rowen DW, Embrey JP, Moore CH, Welch SP. Antisense oligodeoxynucleotides to the kappa1 receptor enhance delta9-THC-induced antinociceptive tolerance. Pharmacol Biochem Behav 1998; 59: 399-404. (Pubitemid 28072734)
140. Fuentes JA, Ruiz-Gayo M, Manzanares J, Vela G, Reche I, Corchero J. Cannabinoids as potential new analgesics. Life Sci 1999; 65: 675-685
141. Ghozland S, Matthes HW, Simonin F, Filliol D, Kieffer BL, Maldonado R. Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid receptors. J Neurosci 2002; 22: 1146-1154 (Pubitemid 34141794)
142. Castañé A, Robledo P, Matifas A, Kieffer BL, Maldonado R. Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid receptor knockout mice. Eur J Neurosci 2003; 17: 155-159 (Pubitemid 36098886)
143. Valverde O, Maldonado R, Valjent E, Zimmer AM, Zimmer A. Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice. J Neurosci 2000; 20: 9284-9289 (Pubitemid 32042932)
144. Zimmer A, Valjent E, Konig M, Zimmer AM, Robledo P, Hahn H, et al. Absence of delta -9-tetrahydrocannabinol dysphoric effects in dynorphin-deficient mice. J Neurosci 2001; 21: 9499-9505 (Pubitemid 33096894)
145. Gardell LR, Ossipov MH, Vanderah TW, Lai J, Porreca F. Dynorphin-independent spinal cannabinoid antinociception. Pain 2002; 100: 243-248
146. Corchero J, Manzanares J, Fuentes JA. Cannabinoid/opioid crosstalk in the central nervous system. Crit Rev Neurobiol 2004; 16: 159-172 (Pubitemid 39586914)
147. Valverde O, Ledent C, Beslot F, Parmentier M, Roques BP. Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors. Eur J Neurosci 2000; 12: 533-539 (Pubitemid 30142754)
148. Páldyová E, Bereczki E, Sántha M, Wenger T, Borsodi A, Benyhe S. Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors. Neurochem Int 2008; 52: 321-328 (Pubitemid 350235710)
149. Páldy E, Bereczki E, Sántha M, Wenger T, Borsodi A, Zimmer A, et al. CB(2) cannabinoid receptor antagonist SR144528 decreases mu-opioid receptor expression and activation in mouse brainstem: role of CB(2) receptor in pain. Neurochem Int 2008; 53: 309-316
150. Cichewicz DL, Welch SP, Smith FL. Enhancement of transdermal fentanyl and buprenorphine antinociception by transdermal delta9-tetrahydrocannabinol. Eur J Pharmacol 2005; 525: 74-82.
151. Yesilyurt O, Dogrul A, Gul H, Seyrek M, Kusmez O, Ozkan Y, et al. Topical cannabinoid enhances topical morphine antinociception. Pain 2003; 105: 303-308 (Pubitemid 37162500)
152. Corchero J, Avila MA, Fuentes JA, Manzanares J. delta-9- Tetrahydrocannabinol increases prodynorphin and proenkephalin gene expression in the spinal cord of the rat. Life Sci 1997; 61: PL 39-43. (Pubitemid 27305585)
153. Corchero J, Manzanares J, Fuentes JA. Repeated administration of delta9-tetrahydrocannabinol produces a differential time related responsiveness on proenkephalin, proopiomelanocortin and corticotropin releasing factor gene expression in the hypothalamus and pituitary gland of the rat. Neuropharmacology 1999; 38: 433-439 (Pubitemid 29097726)
154. Corchero J, Romero J, Berrendero F, Fernandez-Ruiz J, Ramos JA, Fuentes JA, et al. Time-dependent differences of repeated administration with
155. da Fonseca Pacheco D, Klein A, de Castro Perez A, da Fonseca Pacheco CM, de Francischi JN, Duarte ID. The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid receptors, induces peripheral antinociception mediated by cannabinoid receptors. Br J Pharmacol 2008; 154: 1143-1149 (Pubitemid 351923053)
156. Wilson AR, Maher L, Morgan MM. Repeated cannabinoid injections into the rat periaqueductal gray enhance subsequent morphine antinociception. Neuropharmacology 2008; 55: 1219-1225
157. Welch SP. Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems. Drug Alcohol Depend 1997; 45: 39-45.
158. Fowler CJ, Jonsson KO, Tiger G. Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleamide. Biochem Pharmacol 2001; 62: 517-526 (Pubitemid 32738763)
159. Smith PB, Martin BR. Spinal mechanisms of delta 9-tetrahydrocannabinol- induced analgesia. Brain Res 1992; 578: 8-12.
160. Cichewicz DL, Welch SP. Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther 2003; 305: 812-817
161. Cichewicz DL, McCarthy EA. Antinociceptive synergy between delta(9)-tetrahydrocannabinol and opioids after oral administration. J Pharmacol Exp Ther 2003; 304: 1010-1015
162. Smith PA, Selley DE, Sim-Selley LJ, Welch SP. Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. Eur J Pharmacol 2007; 571: 129-137
163. Roberts JD, Gennings C, Shih M. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol 2006; 530: 54-58. (Pubitemid 43037124)
164. Tham SM, Angus JA, Tudor EM, Wright CE. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice. Br J Pharmacol 2005; 144: 875-884
165. Williams J, Haller VL, Stevens DL, Welch SP. Decreased basal endogenous opioid levels in diabetic rodents: effects on morphine and delta-9- tetrahydrocannabinoid-induced antinociception. Eur J Pharmacol 2008; 584: 78-86.
166. Tuboly G, Mecs L, Benedek G, Horvath G. Antinociceptive interactions between anandamide and endomorphin-1 at the spinal level. Clin Exp Pharmacol Physiol 2008; PMID: 19018802.
167. Cox ML, Haller VL, Welch SP. Synergy between delta9-tetrahydrocannabinol and morphine in the arthritic rat. Eur J Pharmacol 2007; 567: 125-130
168. Sutters KA, Miaskowski C, Taiwo YO, Levine JD. Analgesic synergy and improved motor function produced by combinations of mu-delta- and mu-kappa-opioids. Brain Res 1990; 530: 290-294 (Pubitemid 20340709)
169. Welch SP, Eads M. Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res 1999; 848: 183-190. (Pubitemid 30001667)
170. Welch SP, Thomas C, Patrick GS. Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine. J Pharmacol Exp Ther 1995; 272: 310-321
171. Viganò D, Grazia Cascio M, Rubino T, Fezza F, Vaccani A, Di Marzo V, et al. Chronic morphine modulates the contents of the endocannabinoid, 2-arachidonoyl glycerol, in rat brain. Neuropsychopharmacology 2003; 28: 1160-1167
172. González S, Schmid PC, Fernández-Ruiz J, Krebsbach R, Schmid HH, Ramos JA. Region-dependent changes in endocannabinoid transmission in the brain of morphine-dependent rats. Addict Biol 2003; 8: 159-166 (Pubitemid 36859656)
173. Rubino T, Tizzoni L, Viganò D, Massi P, Parolaro D. Modulation of rat brain cannabinoid receptors after chronic morphine treatment. Neuroreport 1997; 8: 3219-3223 (Pubitemid 27461370)
174. Romero J, Fernández-Ruiz JJ, Vela G, Ruiz-Gayo M, Fuentes JA, Ramos JA. Autoradiographic analysis of cannabinoid receptor binding and cannabinoid agonist-stimulated [35S]GTP gamma S binding in morphine-dependent mice. Drug Alcohol Depend 1998; 50: 241-249
175. Shapira M, Gafni M, Sarne Y. Independence of, and interactions between, cannabinoid and opioid signal transduction pathways in N18TG2 cells. Brain Res 1998; 806: 26-35. (Pubitemid 29009571)
176. Gonzalez S, Fernandez-Ruiz J, Sparpaglione V, Parolaro D, Ramos JA. Chronic exposure to morphine, cocaine or ethanol in rats produced different effects in brain cannabinoid CB(1) receptor binding and mRNA levels. Drug Alcohol Depend 2002; 66: 77-84.
177. Páldyová E, Bereczki E, Sántha M, Wenger T, Borsodi A, Benyhe S. Altered gene expression and functional activity of opioid receptors in the cerebellum of CB1 cannabinoid receptor knockout mice after acute treatments with cannabinoids. Acta Biol Hung 2007; 58: 113-129 (Pubitemid 351178247)
178. Fattore L, Viganò D, Fadda P, Rubino T, Fratta W, Parolaro D. Bidirectional regulation of mu-opioid and CB1-cannabinoid receptor in rats self-administering heroin or WIN 55,212-2. Eur J Neurosci 2007; 25: 2191-2200 (Pubitemid 46581742)
179. Massi P, Vaccani A, Rubino T, Parolaro D. Cannabinoids and opioids share cAMP pathway in rat splenocytes. J Neuroimmunol 2003; 145: 46-54. (Pubitemid 37485967)
180. Rios C, Gomes I, Devi LA. mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 2006; 148: 387-395 (Pubitemid 43882074)
181. Christie MJ. Opioid and cannabinoid receptors: friends with benefits or just close friends? Br J Pharmacol 2006; 148: 385-386
182. Williams IJ, Edwards S, Rubo A, Haller VL, Stevens DL, Welch SP. Time course of the enhancement and restoration of the analgesic efficacy of codeine and morphine by delta9- tetrahydrocannabinol. Eur J Pharmacol 2006; 539: 57-63. (Pubitemid 44208807)
183. Shapira M, Vogel Z, Sarne Y. Opioid and cannabinoid receptors share a common pool of GTP-binding proteins in cotransfected cells, but not in cells which endogenously coexpress the receptors. Cell Mol Neurobiol 2000; 20: 291-304. (Pubitemid 30228222)
184. Salio C, Fischer J, Franzoni MF, Mackie K, Kaneko T, Conrath M. CB1-cannabinoid and mu-opioid receptor co-localization on postsynaptic target in the rat dorsal horn. Neuroreport 2001; 12: 3689-3692 (Pubitemid 33105152)
185. Rodriguez JJ, Mackie K, Pickel VM. Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci 2001; 21: 823-833 (Pubitemid 32163123)
186. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ. Anatomy of CNS opioid receptors. Trends Neurosci 1988; 11: 308-314
187. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991; 11: 563-583
188. Hohmann AG, Briley EM, Herkenham M. Pre- and postsynaptic distribution of cannabinoid and mu opioid receptors in rat spinal cord. Brain Res 1999; 822: 17-25. (Pubitemid 29222825)
189. Houser SJ, Eads M, Embrey JP, Welch SP. Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide. Brain Res 2000; 857: 337-342
190. Mason DJ Jr, Lowe J, Welch SP. A diminution of delta9-tetrahydro- cannabinol modulation of dynorphin A-(1-17) in conjunction with tolerance development. Eur J Pharmacol 1999; 381: 105-111
191. Casanova ML, Blázquez C, Martínez-Palacio J, Villanueva C, Fernández-Aceñero MJ, Huffman JW, et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 2003; 111: 43-50.
192. Kauser S, Schallreuter KU, Thody AJ, Gummer C, Tobin DJ. Regulation of human epidermal melanocyte biology by beta-endorphin. J Invest Dermatol 2003; 120: 1073-1080 (Pubitemid 36702920)
193. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, et al. CB2 cannabinoid receptor activation produces anti-nociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA 2005; 102: 3093-3098 (Pubitemid 40299921)
194. Corchero J, Fuentes JA, Manzanares J. delta 9-Tetrahydro-cannabinol increases proopiomelanocortin gene expression in the arcuate nucleus of the rat hypothalamus. Eur J Pharmacol 1997; 323: 193-195 (Pubitemid 27152270)
195. Yao BB, Hsieh GC, Frost JM, Fan Y, Garrison TR, Daza AV, et al. In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models. Br J Pharmacol 2008; 153: 390-401.
196. Whiteside GT, Gottshall SL, Boulet JM, Chaffer SM, Harrison JE, Pearson MS, et al. (2005) A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833. Eur J Pharmacol 2005; 528: 65-72.
197. Noyes R Jr, Brunk SF, Avery DA, Canter AC. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 1975; 18: 84-89
198. Campbell FA, Tramèr MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001; 323: 13-16 (Pubitemid 32681998)
199. Frank B, Serpell MG, Hughes J, Matthews JN, Kapur D. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ 2008; 336: 199-201. (Pubitemid 351212676)
200. Sawynok J. Topical and peripherally acting analgesics. Pharmacological Reviews 2003; 55: 1-20.
201. Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden A, Brenneisen R. The analgesic effect of oral delta-9- tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 2003; 105: 79-88. (Pubitemid 37162476)
202. Narang S, Gibson D, Wasan AD, Ross EL, Michna E, Nedeljkovic SS, et al. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain 2008; 9: 254-264 (Pubitemid 351471910)
203. Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anaesth 2006; 53: 769-775 (Pubitemid 44420062)
204. Holtman JR, Crooks PA. Patent form no WO/2008/045556: Novel synergistic opioid-cannabinoid codrug for pain management, World Intellectual Property Organization (agent: Davidson CM, Davidson, Davidson & Kappel). New York 2008.